Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	41.96	42.93	90.47	149.8	228.7	147.45
Short-Term Investments	0	0	0	0	39.99	0.25
Cash & Cash Equivalents	41.96	42.93	90.47	149.8	268.69	147.69
Cash Growth	-26.32%	-52.55%	-39.61%	-44.25%	81.92%	-54.08%
Receivables	26.62	39.29	40.28	51.58	26.85	38.86
Inventory	25.53	15.69	21.57	36.63	61.02	116.35
Other Current Assets	18.83	20.24	32.86	33.14	14.88	6.63
Total Current Assets	112.94	118.15	185.18	271.15	371.44	309.53
Property, Plant & Equipment	14.66	16.05	34.37	40.61	35.5	39.42
Goodwill and Intangibles	86.08	95.09	131.13	167.17	199.22	346.27
Other Long-Term Assets	11.79	12.42	5.37	50.42	37.98	75.99
Total Long-Term Assets	112.53	123.55	170.87	258.2	272.7	461.67
Total Assets	225.48	241.7	356.05	529.35	644.14	771.2
Accounts Payable	11.88	14.64	18.02	33.59	41.31	39.22
Deferred Revenue	83.92	83.39	88.03	42.38	40.56	72.95
Current Debt	0	17.5	32	97.54	0	0
Other Current Liabilities	-29.31	-15.65	-8.51	87.54	105.28	95.95
Total Current Liabilities	66.49	99.87	129.54	261.05	187.15	208.12
Long-Term Debt	37.78	26.13	63.04	33.7	121	103.33
Other Long-Term Liabilities	148.47	146.29	158.25	160.59	88.38	64.99
Total Long-Term Liabilities	186.25	172.42	221.29	194.29	209.38	168.33
Total Liabilities	252.74	272.29	350.82	455.34	396.52	376.44
Total Debt	37.78	43.63	95.04	131.25	121	103.33
Debt Growth	-51.38%	-54.09%	-27.59%	8.47%	17.10%	588.89%
Retained Earnings	-1,626.94	-1,608.95	-1,557.03	-1,462.8	-1,177.51	-794.05
Comprehensive Income	0.01	0.01	0.01	0.01	0.01	0
Shareholders' Equity	-27.26	-30.58	5.23	74.01	247.62	394.76
Net Cash / Debt	4.18	-0.71	-4.57	18.55	147.69	44.36
Net Cash / Debt Growth	-	-	-	-87.44%	232.93%	-85.53%
Net Cash Per Share	0.02	-0.00	-0.03	0.11	1.07	0.37
Working Capital	46.46	18.28	55.65	10.1	184.29	101.42
Book Value Per Share	-0.13	-0.16	0.03	0.45	1.79	3.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).